NORDEN
ANNOUNCEMENT NO. 38 - 12 FEBRUARY 2021
In accordance with the adopted remuneration policy for NORDEN, the company has decided to implement a restricted share programme for 2021 similar to the one in 2020.
The overall purpose of the programme is to ensure a shared interest with shareholders and to reward long-term and dedicated work which is deemed to be of value to NORDEN.
Restricted shares will be granted free of charge and remain restricted during a vesting period of 3 years. The programme is expected to be covered by treasury shares. The total number of shares allocated for this program is 76,365 and the total value of the share program is USD 1,437,494 (DKK 8,811,834) based on the Volume Weighted Average Price of the NORDEN share as of 11 February 2021, which is DKK 115.39.
Restricted shares will be granted to Senior Management, a core group of managers and specialists and certain other staff and upon vesting the recipient will receive 1 NORDEN share of nominally DKK 1 for each vested restricted share.
The decision to grant restricted shares is taken on an annual basis by the Board of Directors. Other than being employed by NORDEN at the time of granting of the restricted shares no conditions are attached to the grant. A grant of restricted shares in one year does not entitle the recipient to receive restricted shares in subsequent years. Where a recipient resigns during the vesting period, non-vested restricted shares will lapse.
Kind regards
Dampskibsselskabet NORDEN A/S
Klaus Nyborg
Chairman of the board
For further information:
Klaus Nyborg, Chairman, tel.: +45 3315 0451
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom